U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Biologics Post-Market Activities
  5. Lot Release
  6. Influenza Vaccine for the 2021-2022 Season
  1. Lot Release

Influenza Vaccine for the 2021-2022 Season

Cumulative 2021/2022 Season Lot Release Status (Updated 10/21/2021)

Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.

Manufacturer Total Number of Lots Released by FDA
Afluria Quadrivalent
Seqirus Pty. Ltd.
57
Fluad Quadrivalent
Seqirus, Inc.
24
Fluarix Quadrivalent
GlaxoSmithKline Biologicals
43
Flublok Quadrivalent
Protein Sciences Corporation
40
Flucelvax Quadrivalent
Seqirus, Inc.
56
FluLaval Quadrivalent
ID Biomedical Corporation of Quebec
48
FluMist Quadrivalent
MedImmune, LLC
6
Fluzone High Dose Quadrivalent
Sanofi Pasteur, Inc
34
Fluzone Quadrivalent
Sanofi Pasteur, Inc.
39


FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 5, 2021, to select the influenza viruses for the composition of the influenza vaccine for the 2021-2022 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2020-2021 vaccines, and the availability of candidate strains and reagents.

Influenza virus strains were selected based on the influenza vaccine production method; egg-based and cell- or recombinant based.

The committee recommended that the quadrivalent formulation of egg-based influenza vaccines for the U.S. 2021-2022 influenza season contain the following:

  • an A/Victoria/2570/2019 (H1N1) pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus;
  • a B/Washington/02/2019- like virus (B/Victoria lineage);
  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage). 

The committee recommended that the quadrivalent formulation of cell- or recombinant based influenza vaccines for the U.S. 2021-2022 influenza season contain the following:

  • an A/Wisconsin/588/2019 (H1N1) pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus;
  • a B/Washington/02/2019- like virus (B/Victoria lineage);
  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

For trivalent influenza vaccines for use in the U.S. for the 2021-2022 influenza season, depending on the manufacturing method of the vaccine, the committee recommended that the A(H1N1) pdm09, A(H3N2) and B/Washington/02/2019-like virus (B/Victoria lineage) viruses recommended above for the quadrivalent vaccines be used.

Back to Top